Endocrinology · Medical Literature
Comparative analysis of IDegLira versus insulin glargine in short-term intensive therapy for overweight or obese patients with type 2 diabetes mellitus.
Abstract
To compare the efficacy of insulin degludec/liraglutide (IDegLira) versus insulin glargine, both combined with insulin aspart, for short-term intensive glycemic control in overweight or obese patients with type 2 diabetes mellitus (T2DM). In this randomized study, severely hyperglycemic overweight or obese patients with T2DM received 7-day intensive therapy with either IDegLira plus insulin aspart or insulin glargine plus insulin aspart. The primary endpoint was the proportion of patients achieving high-quality glycemic control [time in range(TIR) > 70%, coefficient of variation (CV) < 36%, and no hypoglycemia]. Secondary endpoints included continuous glucose monitoring (CGM)-derived metrics, insulin requirements, and insulin resistance and β-cell function indices. Compared with controls, the IDegLira group showed higher TIR (84.03% vs. 74.67%, P = 0.007) and lower time above range (TBR) (P = 0.005). Glycemic variability indices, including mean glucose(MG) (8.26 vs. 9.74 mmol/L), were significantly improved (all P ≤ 0.003). The IDegLira group required less insulin (37.95 vs. 41.59 U/d, P = 0.03), achieved glycemic targets faster (3.1 vs. 5.0 days, P < 0.001), and had a higher rate of high-quality glycemic control (65.1% vs. 36.5%, P = 0.001). Short-term reductions in insulin resistance and improvements in β-cell function indices were also observed (all P ≤ 0.001). IDegLira combined with insulin aspart provides superior short-term glycemic control compared with insulin glargine plus insulin aspart in overweight or obese patients with T2DM, with improved glycemic stability, reduced insulin requirements, faster target attainment, and favorable short-term metabolic changes.
Clinical relevance
In severely hyperglycemic overweight or obese patients with type 2 diabetes mellitus requiring short-term (7-day) intensive therapy, does IDegLira plus insulin aspart achieve superior high-quality glycemic control compared with insulin glargine plus insulin aspart, as measured by a composite CGM-based primary endpoint? __SNAPSHOT__ {"studyDesign":"Randomized controlled trial (open-label, parallel-group; described as 'randomized study' in abstract)","setting":"Not fully reported in abstract; preprint context suggests a Chinese hospital inpatient endocrinology setting, framed within China's Diagnosis-Related Groups (DRG) framework","sampleSize":"Not reported in the abstract; full sample size not extractable from the truncated abstract","population":"Severely hyperglycemic overweight or obese adults with type 2 diabetes mellitus requiring short-term intensive glycemic intervention","intervention":"IDegLira (insulin degludec 100 U/mL + liraglutide 3.6 mg/mL, fixed-ratio combination; initial dose ≤16 units, maximum 50 units) administered once daily subcutaneously, combined with preprandial insulin aspart three times daily; starting total insulin dose 0.5 U/kg/day with 50% as IDegLira and 50% distributed equally across three pre-meal aspart doses","comparator":"Insulin glargine once daily subcutaneously combined with preprandial insulin aspart three times daily; same initial dosing structure (0.5 U/kg/day, 50:50 basal:bolus split)","primaryOutcome":"Proportion of patients achieving high-quality glycemic control, defined as a composite of: time in range (TIR) >70%, coefficient of variation (CV) <36%, and no hypoglycemia — all assessed by continuous glucose monitoring (CGM)","followUp":"7 days (active intensive therapy period); no post-treatment follow-up period reported","fundingSource":"Not reported in abstract"}
Key findings
On the primary composite endpoint, the rate of achieving high-quality glycemic control (TIR >70%, CV <36%, and no hypoglycemia) was significantly higher in the IDegLira group compared with the insulin glargine group (P = 0.001); the absolute proportion in each group is not reported in the truncated abstract. For the primary CGM metric of TIR, the IDegLira group achieved a mean TIR of 84.03% versus 74.67% in the control group (absolute difference 9.36 percentage points [calculated], P = 0.007). Time above range (TAR) was significantly lower in the IDegLira group (P = 0.005); specific TAR values are not reported in the available abstract text. All glycemic variability indices were significantly improved in the IDegLira group, including mean glucose (MG: 8.26 vs. 9.74 mmol/L, absolute difference −1.48 mmol/L [calculated], all P ≤ 0.003) and additional CGM-derived indices including mean of daily differences (MODD), standard deviation (SD), and coefficient of variation (CV). Daily insulin requirements were lower in the IDegLira group (37.95 vs. 41.59 U/day, absolute difference −3.64 U/day [calculated]; p-value truncated in the supplied abstract text and not fully reported). Hypoglycemia incidence (mild and severe) was numerically lower in the IDegLira group, but these differences did not reach statistical significance; no significant between-group difference in adverse events was observed. Improvements in pancreatic β-cell function indices and insulin resistance indices are reported as secondary endpoints in favor of IDegLira, but specific values, confidence intervals, and p-values for these outcomes are not available in the truncated abstract. No NNT can be calculated from the information provided, as the absolute proportions achieving the primary composite endpoint are not reported in the truncated abstract. No confidence intervals are reported for any outcome.
Practice implications
This study addresses a clinically relevant and underexplored question: the optimal regimen for very short-term (7-day) inpatient intensive insulin therapy in overweight or obese patients with T2DM, a population known to exhibit significant insulin resistance that may limit the effectiveness of standard basal-bolus regimens. The findings suggest that substituting insulin glargine with IDegLira as the basal component, combined with insulin aspart, yielded statistically superior CGM-based glycemic metrics over a 7-day period, including higher TIR, lower mean glucose, and reduced glycemic variability. The composite primary endpoint incorporating TIR >70%, CV <36%, and absence of hypoglycemia is clinically meaningful, as it captures both adequacy and stability of glycemic control simultaneously. The insulin-sparing effect (approximately 3.6 U/day less, calculated) is modest but directionally consistent with established IDegLira pharmacology via liraglutide's GLP-1-mediated insulin-sensitizing and glucagon-suppressing actions. IMPORTANT LIMITATIONS ON INTERPRETATION: (1) The abstract is truncated, precluding full evaluation of all reported outcomes, effect sizes, and statistical data. (2) The follow-up duration of 7 days is extremely short, making it impossible to determine whether the observed glycemic advantages translate to clinically meaningful outcomes such as sustained remission, post-discharge glucose control, HbA1c reduction, or reduction in diabetes complications. (3) The study was conducted in a Chinese inpatient setting under the DRG framework, which limits generalizability to outpatient populations, non-Asian ethnic groups, or settings where short-term intensive insulin therapy is not standard practice. (4) The study population — severely hyperglycemic hospitalized patients — represents a highly selected subgroup, and results should not be extrapolated to patients with less severe hyperglycemia or those managed in outpatient settings. (5) IDegLira carries a substantially higher acquisition cost than insulin glargine, and no cost-effectiveness analysis is reported. (6) Open-label design introduces risk of performance and detection bias. Clinicians should view these findings as hypothesis-generating for the short-term intensive use of IDegLira plus aspart rather than as sufficient evidence to recommend routine practice change. __LIMITATIONS__ Abstract is truncated: multiple key statistical values (full p-values, proportions achieving the primary composite endpoint, β-cell function data, body weight changes) are not available for evaluation, substantially limiting the ability to assess the full evidence base.,Extremely short follow-up of 7 days: no data on durability of glycemic benefit, post-discharge outcomes, HbA1c trajectory, or long-term complications are reported.,Open-label design: absence of blinding introduces performance bias (clinician titration behavior) and detection bias, particularly relevant for subjective endpoints and hypoglycemia reporting.,Sample size not reported in the abstract: it is not possible to determine whether the trial was adequately powered for the composite primary endpoint, and the risk of type II error for secondary endpoints (especially hypoglycemia, where differences were non-significant) cannot be assessed.,Single-center or limited-center Chinese inpatient population: results may not generalize to non-Asian populations, outpatient settings, or healthcare systems that do not employ short-term intensive insulin hospitalization.,Surrogate CGM endpoints: TIR, CV, and MG are validated surrogates, but a 7-day trial cannot establish effects on HbA1c, microvascular outcomes, cardiovascular events, or mortality.,Funding source not reported: potential conflicts of interest and industry influence on study design or reporting cannot be excluded.,The liraglutide component of IDegLira is known to cause gastrointestinal adverse effects (nausea, vomiting); the rate and clinical impact of these effects during 7-day intensive use are not reported.,The maximum IDegLira dose cap (50 units of degludec/1.8 mg liraglutide) may limit titration flexibility in severely insulin-resistant patients, potentially introducing a systemic bias against achieving equivalent glycemic targets in the IDegLira arm at higher insulin requirements. __BOTTOM_LINE_CATEGORY__ promising_but_preliminary __BOTTOM_LINE__ This small, short-term randomized trial conducted in a Chinese inpatient setting found that IDegLira plus insulin aspart achieved superior CGM-based glycemic control — including higher TIR, lower mean glucose, and reduced glycemic variability — compared with insulin glargine plus insulin aspart over 7 days in severely hyperglycemic overweight or obese patients with T2DM, with numerically but not statistically significantly fewer hypoglycemic events. The 7-day duration, truncated abstract precluding full data review, open-label design, and absence of patient-important outcomes (HbA1c, complications, post-discharge glucose control) preclude any practice change at this time. These findings are hypothesis-generating and require confirmation in larger, adequately powered, longer-duration trials before this approach can be recommended for routine clinical adoption.